Pyxis Oncology, Inc. (PYXS)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Should You Buy Pyxis Oncology, Inc. (PYXS) After Golden Cross?
Pyxis Oncology, Inc. (PYXS) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, PYXS's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.
Top Cancer Stocks to Buy to Boost Your Portfolio's Health
If the cancer space appeals to you, it's time to consider stocks like Pyxis Oncology, Verastem Oncology and Relay Therapeutics.
Pyxis Oncology: Speculative Buy Opportunity With Multiple Catalysts Ahead
Pyxis Oncology's lead candidate, PYX-201, showed promising response rates in Phase 1 trials but raised safety concerns due to a patient's death. The company's valuation appears deeply discounted, with a P/B ratio of 0.7 compared to a sector median of 2.4, reflecting market pessimism. PYX-201's ongoing trials and upcoming catalysts in 2025-2026 are crucial for addressing safety concerns and demonstrating efficacy across multiple cancer types.
Pyxis Oncology's Cancer Drug Progress Stirs Analyst Concerns
On Wednesday, Pyxis Oncology, Inc. PYXS released preliminary data from the ongoing Phase 1 clinical dose escalation study evaluating PYX-201 in multiple solid tumors.
Pyxis Oncology's Cancer Drug Platform Shows Potential, Analyst Sees Over 190% Upside
Stephens has initiated coverage on Pyxis Oncology Inc PYXS, highlighting the company's technology platform aimed at developing next-gen antibody-drug conjugates (ADCs) with enhanced potency, stability, and tolerability.
Moment Of Truth Approaches For Pyxis Oncology
Pyxis Oncology is an antibody and antibody-drug conjugate developer with initial results from two clinical trials ahead in 2024. Data from a phase 1 study of PYX-201, an ADC targeting extra domain B of fibronectin, in multiple tumor types, are expected in fall 2024. Data from a phase 1 study of PYX-106, an anti-Siglec-15 antibody, in multiple tumor types, are expected by year-end 2024.
Q2 2024 EPS Estimates for Pyxis Oncology, Inc. (NASDAQ:PYXS) Decreased by Analyst
Pyxis Oncology, Inc. (NASDAQ:PYXS – Free Report) – Investment analysts at HC Wainwright lowered their Q2 2024 earnings estimates for shares of Pyxis Oncology in a research note issued on Thursday, May 16th. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn ($0.27) per share for the quarter, down from their previous estimate of ($0.12). HC Wainwright currently has a “Buy” rating and a $7.00 target price on the stock. The consensus estimate for Pyxis Oncology’s current full-year earnings is ($1.09) per share. HC Wainwright also issued estimates for Pyxis Oncology’s Q3 2024 earnings at ($0.15) EPS, Q4 2024 earnings at ($0.16) EPS, FY2024 earnings at ($0.63) EPS, Q1 2025 earnings at ($0.41) EPS, Q2 2025 earnings at ($0.36) EPS, Q3 2025 earnings at ($0.36) EPS, Q4 2025 earnings at ($0.36) EPS, FY2025 earnings at ($1.49) EPS, FY2026 earnings at ($1.27) EPS, FY2027 earnings at ($1.42) EPS and FY2028 earnings at ($0.70) EPS. A number of other research analysts have also issued reports on PYXS. Royal Bank of Canada restated an “outperform” rating and set a $7.00 price target on shares of Pyxis Oncology in a research note on Friday, March 22nd. SVB Leerink initiated coverage on shares of Pyxis Oncology in a research note on Tuesday, January 23rd. They set an “outperform” rating and a $12.00 price target on the stock. BTIG Research initiated coverage on shares of Pyxis Oncology in a research note on Friday, February 9th. They set a “buy” rating and a $8.00 price target on the stock. Leerink Partnrs restated an “outperform” rating on shares of Pyxis Oncology in a research note on Tuesday, January 23rd. Finally, Jefferies Financial Group restated a “buy” rating and set a $10.00 price target on shares of Pyxis Oncology in a research note on Tuesday, May 7th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and an average price target of $8.80. Read Our Latest Research Report on PYXS Pyxis Oncology Stock Down 0.5 % NASDAQ:PYXS opened at $4.15 on Monday. Pyxis Oncology has a 52 week low of $1.35 and a 52 week high of $6.85. The firm has a 50 day moving average of $4.68 and a 200 day moving average of $3.54. The stock has a market capitalization of $244.39 million, a price-to-earnings ratio of -3.05 and a beta of 1.45. Pyxis Oncology (NASDAQ:PYXS – Get Free Report) last posted its earnings results on Saturday, May 11th. The company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.19. The firm had revenue of $16.15 million for the quarter, compared to analysts’ expectations of $4.25 million. Institutional Trading of Pyxis Oncology Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Decheng Capital Management III Cayman LLC acquired a new stake in Pyxis Oncology during the third quarter valued at $650,000. abrdn plc acquired a new stake in Pyxis Oncology during the fourth quarter valued at $1,275,000. Acadian Asset Management LLC acquired a new stake in Pyxis Oncology during the third quarter valued at $26,000. Commonwealth Equity Services LLC acquired a new stake in Pyxis Oncology during the third quarter valued at $26,000. Finally, Schulhoff & Co. Inc. acquired a new stake in Pyxis Oncology during the third quarter valued at $44,000. Institutional investors and hedge funds own 39.09% of the company’s stock. About Pyxis Oncology (Get Free Report) Pyxis Oncology, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody, which is in Phase 1 clinical trial for the treatment of solid tumors, including non-small cell lung cancer (NSCLC) without driver mutations/translocations, breast cancer, endometrial cancer, thyroid cancer, kidney cancer, cholangiocarcinoma, bladder cancer, colorectal cancer, and head and neck squamous cell carcinoma. See Also Five stocks we like better than Pyxis Oncology What Does a Stock Split Mean? MarketBeat Week in Review – 5/13 – 5/17 What does consumer price index measure? Take-Two Interactive Software Offers 2nd Chance for Investors 3 Fintech Stocks With Good 2021 Prospects Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook
